TEM5/GPR124 Antibody (499716) [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # FAB8896E
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG2B Clone # 499716
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Chinese hamster ovary cell line CHO-derived recombinant human TEM5/GPR124
Met1-Leu699
Accession # Q96PE1
Met1-Leu699
Accession # Q96PE1
Specificity
Detects human TEM5/GPR124 in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for TEM5/GPR124 Antibody (499716) [DyLight 405]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: TEM5/GPR124
Long Name
Tumor Endothelial Marker 5
Alternate Names
GPR124, KIAA1531
Gene Symbol
GPR124
Additional TEM5/GPR124 Products
Product Documents for TEM5/GPR124 Antibody (499716) [DyLight 405]
Product Specific Notices for TEM5/GPR124 Antibody (499716) [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...